In the phase 3 study, Relatlimab (anti-LAG3, lymphocyte activation gene-3) in combination with Nivolumab (anti-PD-1) provided a greater progression-free survival (PFS) benefit than Nivolumab monotherapy in melanoma patients (2), leading to regulatory approval by USA FDA to treat unresectable or metastatic melanoma. Here, LAG3 is linked to metastatic melanoma.